National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
SLAS Discov. 2021 Dec;26(10):1243-1255. doi: 10.1177/24725552211026238. Epub 2021 Jul 5.
A diverse range of biochemical and cellular assays are used by medicinal chemists to guide compound optimization. The data collected from these assays influence decisions taken on structure-activity relationship (SAR) campaigns. Therefore, it is paramount that medicinal chemists have a solid understanding of the strengths and limitations of each assay being used to characterize synthesized analogs. For the successful execution of a medicinal chemistry campaign, it is our contention that an early partnership among assay biologists, informaticians, and medicinal chemists must exist. Their combined skill sets are necessary to not only design and develop robust assays but also implement an effective screening cascade in which multiple orthogonal and counter assays are selected to validate the activity and target(s) of the synthesized compounds. We review multiple cases of drug and chemical probe discovery from collaborative National Center for Advancing Translational Sciences/National Institutes of Health projects and published scientific literature in which the evaluation of compounds in secondary or orthogonal assays led to the discovery of unexpected activities, forcing a reconsideration of the original assay design that was used to discover the biological activity of the compound. Using these retrospective case studies, the goal of this Perspective is to hedge toward the development of physiologically relevant assays that are able to capture the true bioactivity of compounds being developed in a medicinal chemistry campaign.
药物化学家使用各种生化和细胞分析方法来指导化合物优化。这些分析方法所收集的数据会影响对结构-活性关系 (SAR) 研究的决策。因此,药物化学家必须充分了解用于表征合成类似物的每种分析方法的优缺点,这一点至关重要。我们认为,要成功开展药物化学研究,分析生物学家、信息学家和药物化学家之间必须尽早建立合作关系。他们的综合技能不仅对于设计和开发强大的分析方法,而且对于实施有效的筛选级联至关重要,在筛选级联中,需要选择多个正交和对照分析方法来验证合成化合物的活性和(或)靶标。我们回顾了多个来自国家转化医学科学中心/美国国立卫生研究院合作项目的药物和化学探针发现案例,以及已发表的科学文献,其中化合物在二次或正交分析中的评估导致了意外活性的发现,这迫使人们重新考虑用于发现化合物生物活性的原始分析设计。通过使用这些回顾性案例研究,本文旨在开发能够捕捉药物化学研究中开发的化合物真实生物活性的生理相关分析方法。